In its long clinical history, the Carbomedics valve has demonstrated the utmost reliability and safety, with no post-operative structural failures and very low incidence of complications. The enhanced orifice hinge design allows for low thrombogenicity, minimizing pannus overgrowth. The inner surfaces of the pivots are completely open to the flow for washing when the leaflets are closed.
The effectiveness of the Carbomedics design is reflected in the low linearized rates (%/pt-yr) of thromboembolic events reported in published scientific literature.
Twenty-Year Experience With the Carbomedics Mechanical Valve Prosthesis
These outstanding clinical results are confirmed by over twenty years of published follow up.8
* Pooled analysis of cited references. If follow-up years for subgroups (AVR, MVR) was not reported in the paper, their value was calculated from event rates values and graphs data, and the most conservative value inferred was performed.
Freedom from valve-related mortality after mitral and aortic valve replacement*
* All sudden or unknown causes of death were considered valve related in accordance to the Guidelines for reporting morbidity and mortality after cardiac valvular operations.9
Utmost reliability with low thrombogenicity
Thrombogenicity remains to date one of the major concerns related to the implantation of mechanical heart valves. The safety of the Carbomedics valve with respect to thrombogenicity has been extensively proven in published scientific literature and is well recognized by the current European guidelines for heart valve disease management, which classify Carbomedics as a low thrombogenic prosthesis.10
Carbomedics valves have proven to be safe even at INR ranges well below the recommended target.11,12,13